Immunic, Inc. (IMUX)
NASDAQ:IMUX
Want to see IMUX full AI Analyst Report?
IMUX Stock Chart & Stats
$1.00
-$0.01(-1.34%)
At close: 4:00 PM EST
$1.00
-$0.01(-1.34%)
Day’s Range― - ―
52-Week Range$5.06 - $15.77
Previous CloseN/A
Volume261.21K
Average Volume (3M)311.25K
Market Cap
$193.02M
Enterprise Value-$38.57M
Total Cash (Recent Filing)$186.63M
Total Debt (Recent Filing)$421.00K
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 06, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.98
Shares Outstanding13,621,483
10 Day Avg. Volume261,406
30 Day Avg. Volume311,249
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-12.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.97
Enterprise Value/Market Cap-0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.17K
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$36.50Price Target Upside3550.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Evidence - Phase 2 CALLIPERRobust Phase 2 CALLIPER results, including a unified Confirmed Disability Change endpoint and safety comparable to placebo in 467 patients, materially strengthen the clinical rationale. This durable evidence raises the probability of phase 3 success, supports neuroprotective positioning, and aids long-term regulatory and commercial planning.
Strengthened Leadership With MS Commercial ExperienceAdding a CEO with direct MS launch experience and a board chair with proven neurology commercialization track records materially improves execution capability. This enhances regulatory strategy, payer access planning and commercial-readiness over the next 2–6+ months, lowering commercialization execution risk if pivotal data are positive.
Low Financial LeverageMinimal debt reduces fixed financial obligations and interest risk, providing flexibility to structure future financings or partnerships. Over time this lowers bankruptcy risk versus highly leveraged peers and preserves operational optionality to fund pivotal trials or invest in commercialization when paired with strategic capital raises.
Bears Say
No Revenue And Large Persistent LossesAs a pre-revenue biotech, continued multi‑year net losses mean the company must rely on external capital until commercialization. Persistent high losses erode runway, raise dilution risk from equity raises, and create sustained uncertainty about timing of self-sustaining cash flows absent successful regulatory approvals and product launches.
Sustained Negative Free Cash FlowDeep and worsening negative free cash flow forces reliance on financing to fund operations and pivotal trials. This constrains strategic flexibility, may necessitate dilutive equity or restrictive financing terms, and limits the company's ability to self-fund commercialization investments or expand the pipeline without partners.
Balance Sheet Variability From Episodic FinancingMarked swings in stockholders’ equity indicate episodic, sizable financings that alter capital structure. This variability complicates runway forecasting, signals dependence on one-off financings, and can undermine investor confidence and long-term planning compared with a steadier capital base or predictable revenue.
Immunic News
IMUX FAQ
What was Immunic, Inc.’s price range in the past 12 months?
Immunic, Inc. lowest stock price was $5.06 and its highest was $15.77 in the past 12 months.
What is Immunic, Inc.’s market cap?
Immunic, Inc.’s market cap is $193.02M.
When is Immunic, Inc.’s upcoming earnings report date?
Immunic, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.
How were Immunic, Inc.’s earnings last quarter?
Immunic, Inc. released its earnings results on May 13, 2026. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$0.688 by -$0.392.
Is Immunic, Inc. overvalued?
According to Wall Street analysts Immunic, Inc.’s price is currently Undervalued.
Does Immunic, Inc. pay dividends?
Immunic, Inc. does not currently pay dividends.
What is Immunic, Inc.’s EPS estimate?
Immunic, Inc.’s EPS estimate is -1.18.
How many shares outstanding does Immunic, Inc. have?
Immunic, Inc. has 13,621,483 shares outstanding.
What happened to Immunic, Inc.’s price movement after its last earnings report?
Immunic, Inc. reported an EPS of -$1.08 in its last earnings report, missing expectations of -$0.688. Following the earnings report the stock price went up 8.824%.
Which hedge fund is a major shareholder of Immunic, Inc.?
Currently, no hedge funds are holding shares in IMUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.50 (3550.00% Upside)
$36.50 (3550.00% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 100.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.00%
12-Months-Change
Fundamentals
Return on Equity
-220.75%
Trailing 12-Months
Asset Growth
824.89%
Trailing 12-Months
Company Description
Immunic, Inc.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
IMUX Stock 12 Month Forecast
Average Price Target
$36.50
▲(3550.00% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―
Ownership Overview
9.28% Insiders
8.52% Mutual Funds
<0.01% Other Institutional Investors
77.96% Public Companies and Individual Investors